AMRX Quote, Financials, Valuation and Earnings

Eyenovia has a net margin of -0.02% compared to Amneal Pharmaceuticals's net margin of -485406.34%. Amneal Pharmaceuticals's return on equity of -587.3% beat Eyenovia's return on equity of -676.86%.

Amneal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 34.79%. On the other hand Eyenovia has an analysts' consensus of -- which suggests that it could grow by 4042.01%. Given that Eyenovia has higher upside potential than Amneal Pharmaceuticals, analysts believe Eyenovia is more attractive than Amneal Pharmaceuticals.

Amneal Pharmaceuticals has a beta of 1.122, which suggesting that the stock is 12.18% more volatile than S&P 500. In comparison Eyenovia has a beta of 1.434, suggesting its more volatile than the S&P 500 by 43.383%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eyenovia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Eyenovia pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $702.5M, which are larger than Eyenovia quarterly revenues of $1.6K. Amneal Pharmaceuticals's net income of -$156K is higher than Eyenovia's net income of -$7.9M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is -- while Eyenovia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.86x versus 144.49x for Eyenovia. Usually stocks with elevated PS ratios are considered overvalued.

KORU Medical Systems has a net margin of -0.02% compared to Amneal Pharmaceuticals's net margin of -19.33%. Amneal Pharmaceuticals's return on equity of -587.3% beat KORU Medical Systems's return on equity of -57.92%.

Amneal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 34.79%. On the other hand KORU Medical Systems has an analysts' consensus of -- which suggests that it could grow by 24.05%. Given that Amneal Pharmaceuticals has higher upside potential than KORU Medical Systems, analysts believe Amneal Pharmaceuticals is more attractive than KORU Medical Systems.

Amneal Pharmaceuticals has a beta of 1.122, which suggesting that the stock is 12.18% more volatile than S&P 500. In comparison KORU Medical Systems has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.411%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KORU Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. KORU Medical Systems pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $702.5M, which are larger than KORU Medical Systems quarterly revenues of $8.2M. Amneal Pharmaceuticals's net income of -$156K is higher than KORU Medical Systems's net income of -$1.6M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is -- while KORU Medical Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.86x versus 5.65x for KORU Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -0.02% compared to Amneal Pharmaceuticals's net margin of 8.48%. Amneal Pharmaceuticals's return on equity of -587.3% beat Eli Lilly and's return on equity of 66.4%.

Amneal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 34.79%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.58%. Given that Amneal Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Amneal Pharmaceuticals is more attractive than Eli Lilly and.

Amneal Pharmaceuticals has a beta of 1.122, which suggesting that the stock is 12.18% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amneal Pharmaceuticals quarterly revenues are $702.5M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Amneal Pharmaceuticals's net income of -$156K is lower than Eli Lilly and's net income of $970.3M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 86.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.86x versus 17.62x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of -0.02% compared to Amneal Pharmaceuticals's net margin of -211%. Amneal Pharmaceuticals's return on equity of -587.3% beat Nutriband's return on equity of -69.58%.

Amneal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 34.79%. On the other hand Nutriband has an analysts' consensus of -- which suggests that it could grow by 352.26%. Given that Nutriband has higher upside potential than Amneal Pharmaceuticals, analysts believe Nutriband is more attractive than Amneal Pharmaceuticals.

Amneal Pharmaceuticals has a beta of 1.122, which suggesting that the stock is 12.18% more volatile than S&P 500. In comparison Nutriband has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.193%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $702.5M, which are larger than Nutriband quarterly revenues of $645.8K. Amneal Pharmaceuticals's net income of -$156K is higher than Nutriband's net income of -$1.4M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.86x versus 19.51x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.